BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Core Viewpoint - BioSig Technologies, Inc. has regained compliance with Nasdaq listing requirements, allowing its common stock to continue trading on The Nasdaq Capital Market [1][2][3] Company Compliance - On March 24, 2025, BioSig received confirmation from Nasdaq that it met the minimum stockholders' equity threshold of $2.5 million, resolving a previously disclosed deficiency [2] - The company is now in full compliance with all applicable Nasdaq continued listing standards [2] Leadership Statement - CEO Anthony Amato expressed satisfaction with the company's regained compliance, emphasizing a commitment to corporate governance and financial stability [3] - The company aims to deliver long-term value to shareholders and is focused on advancing operational goals and strengthening market position [3] Strategic Focus - BioSig is committed to innovation, strategic partnerships, and investments in advanced technologies to meet shareholder expectations [3] - Further details on specific initiatives and partnerships will be announced as they progress [3] Company Overview - BioSig Technologies is a medical device technology company with the PURE EP™ Platform, which enhances signal processing for electrophysiologists in treating cardiovascular arrhythmias [4][5] - The PURE EP™ Platform allows for real-time acquisition of raw signal data, improving procedural success and efficiency [5]